Hjem › Hode- og halskreft › Tennessee
Kliniske studier for Hode- og halskreft i Tennessee
23 studier for Hode- og halskreft søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site#0126, Nashville
- Site #0116, Nashville
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06788990A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07090499DESTINY-PANTUMOUR04
- Research Site, Nashville
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Sarah Cannon and HCA Research Institute, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT07462377Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]
- Barbara Murphy, Nashville
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06125743A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06819228First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- The West Clinic, PLLC dba West Cancer Center, Germantown
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT05768139Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT07460765Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
- Vanderbilt University Medical Center, Nashville
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT06837480A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Baptist Memorial Hospital Baptist Cancer Center, Memphis
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 27. mai 2026 · NCT03093116A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Chattanooga
- GSK Investigational Site, Germantown
- GSK Investigational Site, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 26. mai 2026 · NCT06256588High-Resolution PET-CT Imaging for Surgical Margin Visualization
- Vanderbilt University Medical Center, Nashville
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 8. mai 2026 · NCT06915454Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06239194cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
- Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Nashville
- Veterans Affairs Medical Center - Nashville, Nashville
- og 1 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT00898638A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2025 · NCT05941507Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. aug. 2025 · NCT04429542Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
- Thompson Proton Center, Knoxville
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 8. apr. 2025 · NCT06183268Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererFase 1/2
Alder 21 og eldre · Alle kjønn · Oppdatert 21. okt. 2024 · NCT05156060Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.